PharmaFocus Today – Page 86 – media

LH-1801 project enters Phase III clinical trial

On July 3, Lianhuan Pharmaceutical(600513) announced that the company has recently conducted a specific object survey with a number of investment institutions. The event was held in Beijing on July 2, 2025, and the participating units included China Asset Management, China Canada Fund and Shibei Investment. The company’s director and general manager Niu Ben and the director of the board office Ge Kai received investors and introduced the company’s development history, technical cooperation and the progress of the projects under research. The LH-1801 project mentioned in the announcement is an SGLT2 inhibitor jointly developed by the company and the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The project has now entered the Phase III clinical trial stage. It is expected that key data will be obtained in the first quarter of next year and an application for listing will be submitted to the National Medical Products Administration in ...
- Source: drugdu
- 451
- July 7, 2025
The new generation of DNA biosynthesis technology is moving towards industrialization

On May 12, 2025, Tianjin Zhonghe Gene Technology Co., Ltd. (hereinafter referred to as Zhonghe Gene) and Tianjin Tianbao Holding Co., Ltd. signed a DNA synthesis project. This marks that the new generation of DNA synthesis technology – enzymatic DNA biosynthesis technology has officially stepped into industrialization, injecting new momentum of “Intelligent Manufacturing in China” into the field of synthetic biology. It is understood that DNA synthesis technology is a key common underlying technology and core enabling technology in synthetic biology. Its synthesis principles are mainly divided into chemical methods and biological methods, and the existing commercialized DNA synthesis technologies and equipment are mainly based on chemical methods. At present, the synthesis length and cost of chemical DNA synthesis methods have reached their limits. However, this technology still has problems such as low single-step accuracy, cumbersome steps for long-fragment DNA synthesis, high synthesis cost, and environmental pollution, which restrict the ...
- Source: drugdu
- 158
- July 7, 2025
The 14th Forum on Innovation and Development of the Pharmaceutical Industry Successfully Held in Shanghai

From June 24 to 25, during the 23rd World Pharmaceutical Raw Materials China Exhibition, the 14th Forum on Innovation and Development of the Pharmaceutical Industry was successfully held in Shanghai. This forum conducted special discussions on hot topics such as the trends of economic and trade restriction measures of the U.S. Trump administration, underwriting and risk analysis of the biopharmaceutical industry chain, review and analysis of China’s pharmaceutical industry development during the “14th Five-Year Plan” and outlook on the development situation during the “15th Five-Year Plan”, the impact and trend prediction of new policies on the pharmaceutical industry, the main characteristics of current pharmaceutical industry development, the development status of China’s generic drug industry, the trends and strategies of pharmaceutical companies entering emerging markets, countermeasures for Chinese export enterprises under the background of Sino-U.S. trade frictions, and the core advantages of industrial parks. Luo Yang, Deputy Secretary-General of the China ...
- Source: drugdu
- 167
- July 7, 2025
Muhammad Iqbal Chaudhry, Coordinator General of the Standing Committee on Scientific and Technological Cooperation of the Organization of Islamic Cooperation (OIC-COMSTECH), and his delegation paid a visit to the China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE).

On the afternoon of June 10, a delegation of over 10 people, including Professor Muhammad Iqbal Chaudhry, Coordinator General of the Cooperation-Ministerial Standing Committee on Scientific and Technological Cooperation of the Organization of Islamic Cooperation (OIC-COMSTECH), Maggie Lowe, an official from the Commercial Section of the Embassy of Pakistan in China, and Professor Liu Xinmin, Advisor on Traditional Medicine of the World Health Organization and Coordinator for Traditional Chinese Medicine of OIC-COMSTECH, visited the China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE). They held discussions and exchanges with Secretary Meng Dongping of the Chamber and other representatives. The two sides engaged in extensive and lively exchanges on strengthening cooperation between China and the Organization of Islamic Cooperation in the field of traditional medicine under the framework of the SCO Traditional Medicine Industry Alliance, promoting China-Pakistan cooperation in traditional medicine, and facilitating the integration of ...
- Source: drugdu
- 162
- July 7, 2025
CCCMHPIE Joins Hands with International Organizations to Build New Access Channels for Pharmaceutical Markets in Low- and Middle-Income Countries — Medicines Patent Pool (MPP) Docking and Exchange Event Successfully Held in Shanghai

On June 25, 2025, the “Exchange Meeting for Assisting Chinese Enterprises in Entering Pharmaceutical Markets of Low – and Middle – Income Countries” co – hosted by the China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE) and the Medicines Patent Pool (MPP) – a global health organization supported by the United Nations – successfully concluded at the Shanghai New International Expo Center. The event gathered experts from MPP, the United Nations International Drug Purchase Facility (UNITAID), and over 50 Chinese pharmaceutical companies to jointly explore strategic paths for tapping into the global pharmaceutical blue – ocean market with a population of 4.5 billion through innovative international cooperation mechanisms. President Zhou Hui of CCCMHPIE and Dr. Judith Federhofer, Director of Business Development at MPP, attended the forum and delivered speeches. Director Zhang Beibei of the Legal and Comprehensive Department presided over the forum. I. Breaking ...
- Source: drugdu
- 152
- July 7, 2025
The Path of the Biotechnology Industry to Net Zero

The pharmaceutical industry took some time to put sustainable development on the management agenda. However, the industry is now going all out to catch up – with strong support from Zeta. This solution provider is helping the pharmaceutical industry with its low-carbon transformation through its net-zero roadmap and a new business line. Since the EU announced the “European Green Deal”, one thing has become clear: all industries must work together to achieve the goal of zero emissions. The pharmaceutical industry has been slow to progress. But now, pressure from investors and shareholders has prompted leaders in the pharmaceutical and biotechnology industries to pick up the pace. Green energy, sustainable supply chains, and decarbonization of production and bases – many companies are now embarking on the path of green transformation. This can be seen from the sustainable development goals set by industry giants such as Novartis, GSK, or Roche, as well ...
- Source: drugdu
- 132
- July 7, 2025
the first of its kind to achieve the primary endpoint of mid-term analysis in nasopharyngeal carcinoma stage III clinical trials with iza bene

On the evening of July 2nd, Baili Tianheng announced that its independently developed EGFR × HER3 dual antibody ADC (iza bene), which is a first in class, new concept, and the only one to enter the Phase III clinical stage, has reached the primary endpoint in the Phase III clinical trial of nasopharyngeal carcinoma (study protocol number: BL-B01D1-303). The indication is for recurrent or metastatic nasopharyngeal carcinoma that has been previously treated with PD-1/PD-L1 monoclonal antibodies and has failed at least two lines of chemotherapy (at least one line containing platinum). The announcement shows that Iza bren is conducting over 40 clinical trials targeting multiple types of tumors in China and the United States. As of now, Iza bren has 5 indications included in the breakthrough treatment list by the Drug Evaluation Center of the National Medical Products Administration. Baili Tianheng presented Phase I research data on Iza bren treatment ...
- Source: drugdu
- 278
- July 4, 2025
Gout treatment welcomes new choices! Changchun High tech’s first domestically approved injection of Fuxinqibai monoclonal antibody for market launch

On the evening of July 2nd, Changchun High tech announced that its subsidiary Jinsai Pharmaceutical, which is controlled by the company, has obtained approval from the National Medical Products Administration for the injection of Fuxinqibai monoclonal antibody (formerly known as Jinna monoclonal antibody for injection). This drug is the first domestically approved IL-1 inhibitor for the treatment of acute attacks of gouty arthritis, and its precise and long-lasting anti-inflammatory advantages will bring new treatment options for gout patients. It is reported that Fuxinqibai monoclonal antibody for injection is a new type of fully human anti-IL-1 β monoclonal antibody drug developed by the company. It belongs to the first class of therapeutic biological products and can specifically bind to human IL-1 β, block the production of inflammatory mediators induced by IL-1 β. It is suitable for acute attacks of gouty arthritis in adults who are contraindicated, intolerant or lack efficacy of ...
- Source: drugdu
- 272
- July 4, 2025
this is the path to carbon neutrality

Is it possible to achieve carbon – dioxide – free operation of pharmaceutical warehouses? The answer is yes. United Therapeutics, a biopharmaceutical company, has built a Good Manufacturing Practice (GMP) – compliant warehouse in North Carolina, southern United States, which is worthy of being called a milestone project. Next, let’s take a closer look at the details. Generally, GMP – compliant pharmaceutical warehouses are not energy – efficient buildings. The temperature – control system needs to run continuously, the air humidity needs to be kept stable, and the whole system also needs to go through strict verification. The power consumption of the air – conditioning system is huge, and when a cryogenic area needs to be set up for sensitive active ingredients, the energy consumption is doubled. All in all, these conditions are not ideal for designing a net – zero energy – consumption building. Nevertheless, it is indeed feasible. ...
- Source: drugdu
- 119
- July 4, 2025
Dizal (Jiangsu) Pharmaceutical Co., Ltd. Voluntary Disclosure of Announcement Regarding Accelerated Marketing Approval of Suvoderm® by the U.S. FDA

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) has officially received approval from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) of its independently developed Sulvoteran® (English trade name: ZEGFROVY®, generic name: Sulvotinib Tablets). It is indicated for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations (Exon20ins) as detected by an FDA-approved testing kit, whose disease has progressed during or after platinum-containing chemotherapy. Sulvoteran® was approved for marketing through the Priority Review process, becoming the world’s first and currently the only domestically innovative drug approved in the U.S. for EGFR Exon20ins NSCLC. It has achieved significant innovations in molecular design at the source, breaking through intractable targets, and is China’s first globally first-in-class innovative drug independently developed and approved in the U.S. I. Information Related to the Drug ...
- Source: drugdu
- 180
- July 4, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.